Beta Bionics (BBNX) CMO awarded 91,520 stock options at $12.63 strike

Rhea-AI Filing Summary

Beta Bionics, Inc. reported that its Chief Medical Officer, Russell Steven Jon, received a grant of stock options. The award covers 91,520 options to purchase common stock at an exercise price of $12.63 per share, expiring on February 26, 2036.

The options were granted at no cost and represent a compensation-related award rather than an open-market purchase. According to the vesting terms, the options will vest in 36 equal monthly installments starting on March 1, 2026, meaning the officer earns the right to exercise them gradually over three years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Steven Jon

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		91,520		(1)	02/26/2036	Common Stock	91,520	$0	91,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Remarks:

The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Beta Bionics (BBNX) report for Russell Steven Jon?

Beta Bionics reported a stock option grant to Chief Medical Officer Russell Steven Jon. He received 91,520 employee stock options, giving him the right to buy common shares at a fixed exercise price as part of his compensation package, rather than an open-market share purchase.

How many stock options did the Beta Bionics (BBNX) CMO receive and at what price?

The Chief Medical Officer received 91,520 employee stock options with an exercise price of $12.63 per share. These options allow future purchase of Beta Bionics common stock at that price if they vest and are exercised before expiration.

When do the newly granted Beta Bionics (BBNX) options to the CMO vest?

The options vest in 36 equal monthly installments starting March 1, 2026. This means one thirty-sixth of the 91,520 options becomes exercisable each month over three years, aligning the officer’s equity compensation with longer-term company performance.

When do the Beta Bionics (BBNX) stock options granted to the CMO expire?

The employee stock options granted to the Chief Medical Officer expire on February 26, 2036. If he does not exercise vested options by that date, they lapse, so the 10-year term defines the maximum period for converting them into common shares.

Was the Beta Bionics (BBNX) CMO’s Form 4/A transaction an open-market buy or a compensation grant?

The transaction was a compensation-related grant, not an open-market purchase. The Form 4/A shows code “A” for grant or award, with 91,520 options issued at no cost, reflecting equity-based pay rather than the insider buying shares on the market.